‘The blue inhaler is a killer,’ says expert

There is “mounting evidence” that it’s time to reduce reliance on short-acting beta2 agonists, say experts A recent controlled trial published in the New England Journal of Medicine found treatment with short-acting beta2 agonists (SABA) alone was inferior to other approaches in terms of asthma attacks. The same study showed as needed combined inhaled corticosteroids